Candel Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $0.1 | $0.1 |
| Operating income | -$48.3 | -$33.4 | -$38.4 | -$34.7 | -$25.7 |
| Net income | -$38.2 | -$55.2 | -$37.9 | -$18.8 | -$36.1 |
| Balance Sheet | |||||
| Total debt | $46.1 | $11.6 | $20.5 | — | — |
| Cash Flow Statement | |||||
| Free cash flow | -$38.9 | -$27.0 | -$34.7 | -$32.7 | -$24.1 |
Shares outstanding 73.3M · Free float 82.0%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.